Follow us on FacebookFollow TorHoermanLaw on TwitterEmail Tor Hoerman Law

Current Litigation

Should you consider the Actos Bladder Cancer Lawsuit as a result of your Bladder Cancer diagnosis?

Takeda Pharmaceutical Co, the manufacturer of Actos (pioglitazone), made more than $16 billion on its blockbuster drug, Actos, prior to it going generic in August of 2012.   While Takeda’s internal Actos studies uncovered links to bladder cancer as early as 2004, the company didn’t alert U.S. regulators until seven years later, according to Actos bladder cancer lawsuits filed by Actos attorneys. 

 

When companies, like Takeda, place profits ahead of safety, injured victims should consider their legal rights – Many injured should consider the Actos Lawsuit.

If you are one of the millions of people that took the diabetes medication Actos, and you developed bladder cancer, you may be entitled to compensation by filing an Actos Lawsuit. 

There are nearly 6,000 Actos Bladder Cancer Cases pending in courts.  These cases are divided between Chicago Actos Bladder Cancer Cases and the Actos lawsuits consolidated in federal court under an MDL (multidistrict litigation)

The lawyers at TorHoerman Law proudly represent clients in the Actos Lawsuit against Takeda Pharmaceutical. 

If you or a loved one was diagnosed with bladder cancer and believe the diagnosis is the result of their use of Actos, our Actos Lawyers will be happy to assess your claim with a quick, no charge evaluation to see if you qualify for the Actos Bladder Cancer Lawsuit.

Actos Bladder Cancer Risk

On June 15, 2011 The FDA issued an Actos FDA Bladder Cancer Warning with regards to an increased bladder cancer risk associated with the use of the diabetes drug Actos.  This warning comes after a review of data from a five-year interim analysis of an ongoing study of Actos by Takeda.

The results showed that although there was no increased risk of bladder cancer among Actos users overall, there was an increased risk of bladder cancer amongst those who had used the drug the longest.  There was also a greater risk of bladder cancer among Actos users who had been exposed to the highest cumulative dose of the drug.

Prior to the FDA warning - several Eurpoean Markets, France and Germany, suspended the use of Actos, citing concerns over an increased risk of patients developing bladder cancer. 

Takeda's Type2 Diabetes drug, Actos, grew in popularity after use of Avandia, GlaxoSmith Kline's controversial drug was severely restricted in the US because of concerns of an increased risk of heart attack and heart failure last fall.  Takeda had profits from sales of Actos in the U.S of over $3 billion in 2009 and just under $3 billion in 2010.

New Studies point to Increased Actos Bladder Cancer Risk

Recent studies continue to point toward Actos Bladder Cancer Risks.  On July 5, 2013, an international independent study was published finding Actos to be “probably carcinogenic.”

On June 2013, twenty-three experts from nine countries met at the International Agency for Research on Cancer (IARC) to assess the carcinogenicity of fourteen drugs and herbal products. After a detailed review of one large randomized controlled study, four cohort studies, and three case controlled studies, the Agency determined that pioglitazone (the active ingredient in Actos) should be classified as probably carcinogenic to humans based on the evidence that it causes bladder cancer.

Actos Bladder Cancer Attorneys, TorHoerman Law, believe that despite Takeda knowing of the Actos Bladder Cancer risk, Takeda promoted and marketed Actos as safe and effective which resulted in many injured individuals.

When companies put profits ahead of safety, TorHoerman Law believes they should be held responsible for their actions.

Actos Bladder Cancer Litigation Moves Forward

To date, two Actos bladder cancer cases have gone to trial.   Actos lawyers in both cases have argued that Takeda put sales over safety when they failed to warn consumers about the risk of bladder cancer associated with Actos. 

According to testimony given at both trials, multiple emails from different levels of Takeda management indicated that sales of the product came before user safety.  Takeda management stressed that the “worst-case scenario” would be for regulators to require the inclusion of bladder cancer in the warning on the Actos Label.   This worst-case scenario ultimately happened, but not for another six years, after many people were diagnosed with bladder cancer. 

Actos Bladder Cancer Lawyers, TorHoerman Law will continue to update the public about all pending Actos lawsuits as they make their way through the court system.  Trials continue through 2014 with the first federal trial scheduled for January of 2014 (In re:Actos Product Liability Litigation MDL No. 2299), followed by the first of the 2,900 cases filed in Cook County  beginning in March of  2014. 

If you feel that your bladder cancer diagnosis may have been the result of your Actos usage, you should consider inclusion in the Actos Lawsuit.   Contact an Actos Cancer Attorney like TorHoerman Law to make sure your legal rights are considered.  TorHoerman Law will tell you honestly whether you should consider participation in the Actos lawsuit.  We are offering a no charge, no obligation review of your medical history for potential inclusion in the Actos Bladder Cancer Lawsuit.

Below you will find timely links to news and blogs with regards to the Actos Lawsuit.

Latest Actos News

    No-Obligation Free Consultation

    Contact us by phone at 1-888-50-TORLAW or email us below.


     

    Your information will be used only so that we may contact you to evaluate your case. Your contact information will never be shared or sold to anyone other than TorHoerman Law.

    Actos Bladder Cancer Risk